Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis

Abu‐Sbeih, Hamzah; S. Ali, Faisal; Rafeh Naqash, Abdul; H. Owen, Dwight; Patel, Sandipkumar; A. Otterson, Gregory; Kendra, Kari; Ricciuti, Biagio; Chiari, Rita; De Giglio, Andrea; Sleiman, Joseph; Funchain, Pauline; Beatriz, Wills; Zhang, Jiajia; Naidoo, Jarushka; Philpott, Jessica; Gao, Jianjun; K. Subudhi, Sumit; Wang, Yinghong

doi:10.1200/jco.19.00320

Public

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis

Published in Journal of Clinical Oncology • Jun 4, 2019

Authors:

Hamzah Abu‐Sbeih

Faisal S. Ali

Abdul Rafeh Naqash

Abstract

PURPOSE Immune checkpoint inhibitor (ICI) therapy often is suspended because of immune-mediated diarrhea and colitis (IMDC). We examined the rate of and risk factors for IMDC recurrence after ICI resumption. METHODS This retrospective multicenter study examined patients who resumed ICI therapy after...

Subject

Medicine

Interquartile range

Discontinuation

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!